Ivan Bergstein
2014
In 2014, Ivan Bergstein earned a total compensation of $3.1M as President and Chief Executive Officer at Stemline Therapeutics, a 7% increase compared to previous year.
Compensation breakdown
| Bonus | $375,000 |
|---|---|
| Non-Equity Incentive Plan | $75,000 |
| Option Awards | $1,463,207 |
| Salary | $500,000 |
| Stock Awards | $722,893 |
| Total | $3,136,100 |
Bergstein received $1.5M in option awards, accounting for 47% of the total pay in 2014.
Bergstein also received $375K in bonus, $75K in non-equity incentive plan, $500K in salary and $722.9K in stock awards.
Rankings
In 2014, Ivan Bergstein's compensation ranked 2,890th out of 13,032 executives tracked by ExecPay. In other words, Bergstein earned more than 77.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,890 out of 13,032 | 78th |
Division Manufacturing | 1,026 out of 4,966 | 79th |
Major group Chemicals And Allied Products | 330 out of 1,686 | 80th |
Industry group Drugs | 257 out of 1,365 | 81st |
Industry Pharmaceutical Preparations | 211 out of 1,043 | 80th |
Source: SEC filing on May 1, 2017.
Bergstein's colleagues
We found three more compensation records of executives who worked with Ivan Bergstein at Stemline Therapeutics in 2014.